Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 17/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 16/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772306 | 1.00 | METTL3 (0.57) | METTL3PRMT5 | |
| SCHEMBL23273897 | 0.91 | PRMT5 (0.65) | METTL3PRMT5 | |
| SCHEMBL29772256 | 0.91 | PRMT5 (0.65) | METTL3PRMT5 | |
| SCHEMBL29772293 | 0.90 | METTL3 (0.57) | METTL3PRMT5 | |
| SCHEMBL23273890 | 0.90 | METTL3 (0.57) | METTL3PRMT5 | |
| SCHEMBL29772303 | 0.90 | METTL3 (0.57) | METTL3PRMT5 | |
| SCHEMBL25015460 | 0.90 | METTL3 (0.47) | METTL3PRMT5 | |
| SCHEMBL23273992 | 0.79 | METTL3 (0.55) | METTL3 | |
| SCHEMBL23313202 | 0.79 | PRMT5 (0.55) | METTL3PRMT5 | |
| SCHEMBL29805211 | 0.79 | METTL3 (0.55) | METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4048674-A2 | METTL3 MODULATORS | Accent Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021079196-A9 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021079196-A2 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027361-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | METTL3 1/4885PRMT5 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.